Accelerate Diagnostics Stock Alpha and Beta Analysis
| AXDX Stock | USD 1.66 0.05 3.11% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Accelerate Diagnostics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Accelerate Diagnostics over a specified time horizon. Remember, high Accelerate Diagnostics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Accelerate Diagnostics' market risk premium analysis include:
Beta (0.63) | Alpha (0.11) | Risk 4.03 | Sharpe Ratio (0.05) | Expected Return (0.19) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Accelerate |
Accelerate Diagnostics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Accelerate Diagnostics market risk premium is the additional return an investor will receive from holding Accelerate Diagnostics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Accelerate Diagnostics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Accelerate Diagnostics' performance over market.| α | -0.11 | β | -0.63 |
Accelerate Diagnostics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Accelerate Diagnostics' Buy-and-hold return. Our buy-and-hold chart shows how Accelerate Diagnostics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Accelerate Diagnostics Market Price Analysis
Market price analysis indicators help investors to evaluate how Accelerate Diagnostics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Accelerate Diagnostics shares will generate the highest return on investment. By understating and applying Accelerate Diagnostics stock market price indicators, traders can identify Accelerate Diagnostics position entry and exit signals to maximize returns.
Accelerate Diagnostics Return and Market Media
The median price of Accelerate Diagnostics for the period between Sat, Aug 31, 2024 and Fri, Nov 29, 2024 is 1.83 with a coefficient of variation of 8.45. The daily time series for the period is distributed with a sample standard deviation of 0.15, arithmetic mean of 1.77, and mean deviation of 0.13. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Ogilvie Marran H. of 66667 shares of Accelerate Diagnostics subject to Rule 16b-3 | 09/10/2024 |
2 | Disposition of 4737 shares by Regan Jennifer of Accelerate Diagnostics subject to Rule 16b-3 | 09/11/2024 |
3 | Accelerate Diagnostics Now Covered by Analysts at StockNews.com | 10/08/2024 |
4 | Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results - StockTitan | 10/25/2024 |
5 | Accelerate Diagnostics Q3 Earnings Preview | 11/06/2024 |
6 | Accelerate Diagnostics Q3 Earnings Snapshot | 11/07/2024 |
7 | Accelerate Diagnostics Inc Q3 2024 Earnings Call Highlights Strategic Advances Amid ... | 11/08/2024 |
8 | Earnings call Accelerate Diagnostics Q3 results and FDA clearances | 11/11/2024 |
About Accelerate Diagnostics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Accelerate or other stocks. Alpha measures the amount that position in Accelerate Diagnostics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Dividend Yield | 2.24E-4 | 2.13E-4 | Price To Sales Ratio | 4.06 | 3.85 |
Accelerate Diagnostics Upcoming Company Events
As portrayed in its financial statements, the presentation of Accelerate Diagnostics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Accelerate Diagnostics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Accelerate Diagnostics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Accelerate Diagnostics. Please utilize our Beneish M Score to check the likelihood of Accelerate Diagnostics' management manipulating its earnings.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Accelerate Diagnostics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Accelerate Stock Analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.